Skip to main content
Clinical Trials/ChiCTR2200061833
ChiCTR2200061833Active, not recruitingNot Applicable

子宫内膜癌及子宫内膜不典型增生保育过程中的早期免疫指标诊断价值研究

医院自有资金1 site in 1 countryStarted: September 15, 2021Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Locations
1
Primary Endpoint
免疫标志

Study Overview

Brief Summary

探索孕激素治疗早期子宫内膜癌患者过程中的免疫机制,分析治疗有效性及背后的分子细胞水平变化,未进一步提高子宫内膜癌患者保育成功率及治疗有效性提供帮助。

Study Design

Study Type
观察性研究
Primary Purpose
病例研究

Eligibility Criteria

Ages
20 to 45 (—)
Sex
Female

Inclusion Criteria

  • 1.病理类型明确为 I 型内膜样癌,病理级别不超过 G2 或病理为子宫内膜不典型增生;
  • 2.MRI 及超声评估后病灶未浸润深肌层;
  • 3.年龄小于等于 40 岁,有强烈意愿者不超过 45 岁;
  • 4.肝肾功能正常,无激素治疗禁忌症;
  • 5.治疗后 1 年左右有进一步生育计划。

Exclusion Criteria

  • 2.内膜癌 FIGO 分期超过 IA 期。

Arms & Interventions

case series

Outcomes

Primary Outcomes

免疫标志

内膜蜕膜化

妊娠结局

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
医院自有资金

Study Sites (1)

Loading locations...

Similar Trials